233 results on '"Spurr, Liam"'
Search Results
2. Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade
3. Emergency Department Preparedness to Care for Sexual Assault Survivors: A Nationwide Study
4. Cancer aneuploidies are shaped primarily by effects on tumour fitness
5. PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery
6. Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
7. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade
8. Tumor aneuploidy predicts survival following immunotherapy across multiple cancers
9. Clinicogenomic characterization of inflammatory breast cancer
10. ASO Visual Abstract: PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence for Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery
11. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy
12. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
13. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer
14. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
15. Author Correction: Tumor aneuploidy predicts survival following immunotherapy across multiple cancers
16. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer.
17. PATH-12. CONTEMPORARY MOLECULAR LANDSCAPE, SURVIVAL, AND PROGNOSTIC FACTORS IN OVER 4,000 GLIOMAS
18. scReQTL: an approach to correlate SNVs to gene expression from individual scRNA-seq datasets
19. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
20. Mechanisms and therapeutic implications of hypermutation in gliomas
21. Genome-resolved metagenomics of an autotrophic thiocyanate-remediating microbial bioreactor consortium
22. Molecular Landscape and Contemporary Prognostic Signatures of Gliomas
23. Data from Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
24. Supplementary Figures Legends from Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
25. Supplementary Tables from Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
26. Figure S6 from Discovery and Features of an Alkylating Signature in Colorectal Cancer
27. Data from Discovery and Features of an Alkylating Signature in Colorectal Cancer
28. Data from FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
29. Supplementary Data from Discovery and Features of an Alkylating Signature in Colorectal Cancer
30. Supplementary Data from FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
31. Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
32. Supplementary Data from Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
33. Supplementary Data from Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
34. Supplementary Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
35. Supplementary Figures from Genomic Characterization of de novo Metastatic Breast Cancer
36. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma
37. STK11Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer
38. Characterization of an autotrophic bioreactor microbial consortium degrading thiocyanate
39. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy
40. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
41. Chromosomal instability mediates immune exclusion and response to cytotoxic chemotherapy in colorectal liver metastases
42. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q
43. Abstract NG01: Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers harboring loss of chromosome 18q or 16q
44. Additional file 1 of scReQTL: an approach to correlate SNVs to gene expression from individual scRNA-seq datasets
45. Discovery and Features of an Alkylating Signature in Colorectal Cancer
46. Selective and mechanistic pressures shaping cancer aneuploidies
47. Changes in PD-L1 tumor proportion score are associated with CD274 gene (encoding PD-L1) copy number variation in non-small cell lung cancer.
48. FGFR2Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
49. Genomic Characterization of de novo Metastatic Breast Cancer
50. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.